Hansa Biopharma
Scheelevägen 22
SE-223 63 Lund, Sweden
Phone: +46 46 16 56 70

www.hansabiopharma.com

PRESS RELEASE

Hansa Biopharma presenting at Stifel 2026 Healthcare Conference

Lund, Sweden, November 5. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President US, Hansa Biopharma, will be presenting at the Stifel 2026 Healthcare Conference, on Thursday 12 November, at 11:20-11:50 EST, at the Lotte New York Palace, NY. Hansa Biopharma CFO Adam Cutler will also be attending the event.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Hansa Biopharma Corporate Presentation at Stifel 2026 Healthcare Conference

Date, Time and Place: Thursday 12 November, 11:20-11:50 EST, Lotte New York Palace, NY

Presenter: Maria Törnsén, COO and President US

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.